Actively Recruiting
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Led by Wake Forest University Health Sciences · Updated on 2026-02-02
120
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
A
Atrium Health Levine Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
CONDITIONS
Official Title
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent and HIPAA authorization for release of personal health information
- Age 18 years or older at the time of consent
- Eligible for standard single-gene DPYD testing (receiving or expected to receive fluoropyrimidine-based chemotherapy)
- Consent must occur within 60 days if DPYD test was previously ordered
- Willing to provide additional buccal swabs if needed for microarray testing
You will not qualify if you...
- History of prior allogeneic hematopoietic cell transplantation or liver transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Atrium Health Levine Cancer
Charlotte, North Carolina, United States, 28204
Actively Recruiting
Research Team
M
Megan Lattanze
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here